This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

Identifying patients with uncontrolled asthma

This section is for primary and secondary care clinicians and how they can support earlier identification of patients who may be eligible for biologics to treat their asthma.

Early identification and healthcare professional training

  • Identification tools– There is a need to improve identification of patients with potentially severe asthma who are inadequately treated/controlled so that their care can be optimised and if required, receive early referral to Severe Asthma Centres.

SPECTRA Tool Identification of SusPECTed seveRe Asthma in Adults

SPECTRA primary care clinical system resources have been developed to help identify adults with potential severe asthma, optimise and where required, refer them to severe asthma centres.

To see the SPECTRA Overview click here.

To see the SPECTRA information slide deck click here.

To see the SPECTRA Practice Level View click here.

To see the Data Protection Impact Assessment DPIA Template click here.

To see the Investment and Impact Fund (IIF) click here.


  • Education/training– Cogora have been commissioned to deliver two tailored educational modules about Identifying and Managing Uncontrolled Asthma and Management of Non-Adherence. The Asthma Biologics Training Package will consist of two e-learning modules, two podcasts and a series of three life webinars. To be launched soon!

NHS Business Services Authority Oral Corticosteroid Metric

In recognition of the need to balance the benefits with the potential harm associated with oral corticosteroid use, a new metric has been developed by the NHS Business Services Authority (NHSBSA), in collaboration with clinicians at Guy’s and St Thomas’ NHS Foundation Trust and the Oxford Academic Health Science Network (AHSN).

It will identify patients with asthma or COPD who have received prednisolone in the last year and as it is possible to search by age group and cumulative amount of prednisolone dispensed, will support prioritisation of those most at risk for review and intervention.

To be launched soon!